In order to complete tens of millions of yuan in A round of financing, Haibo has paralleled R&D and market, and has developed into a world-class innovative pharmaceutical company.

Artery Network learned for the first time that Haibowei (hereinafter referred to as "Haibowei"), a new biopharmaceutical company that focuses on the research and development of innovative drugs, has recently completed a round of financing of tens of millions of yuan.

This round of financing was jointly led by Waige Capital and the Sichuan Academician Science and Technology Innovation Fund (hereinafter referred to as the "Sichuan Academician Fund") under the Sichuan Development Hongke Company.

Dr.

At present, Haibo has raised three rounds of financing, and the accumulated financing exceeds 100 million yuan.

The combination of concept, strategy and technology helps Haibo to become a leading pharmaceutical company in the future

Haibowei is a new-type pharmaceutical company with the goal of leading concept, leading strategy and leading technology.

The founder, Dr.

Dr.

R&D and market are parallel, innovation and profit are both harvested

The company not only has a young and innovative team, but also a development model of a relatively small group of pharmaceutical companies in China.

Unlike other pharmaceutical companies, Haibowei is not a R&D platform purely for innovative drugs.

Haibo has developed a number of internationally leading high-end pharmaceutical intermediates that are green and environmentally friendly and have huge cost advantages for the technical team.

From the current development of China's science and technology innovation version, an enterprise not only needs to have the ability to innovate, but also to have the ability to continuously create value, otherwise it will eventually be eliminated by the market.

Dr.

Discovered the world's first second-generation anti-drug resistant BTK inhibitor with good permeability

In terms of innovation and R&D, Haibowei’s several ongoing research projects are in a fast-advancing stage.

Regarding BTK, its small molecule inhibitors have good specificity and show very good advantages in the treatment of B-cell malignant tumors and some B-cell immune diseases.

According to statistics, there are 75,300 cases of leukemia in my country each year, and the 5-year survival rate of patients is only 24.

HBW-3-20 is the world’s first reported second-generation BTK inhibitor that can substantially penetrate the blood-brain barrier, is reversible, and is resistant to drug resistance.
It has been tested in preclinical head-to-head comparisons of intracerebral lymphoma animal models.
HBW-3-20's tumor suppressive effect is much better than that of Ono Pharmaceuticals, Japan, which is the world's first and only first-generation brain-permeable BTK inhibitor Tirabrutinib for central nervous lymphoma.

HBW-3-20 can be used for the treatment of primary central nervous system lymphoma and lymphoma brain metastases, as well as autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis) and central nervous system related diseases Treatment is of great development value.
According to relevant laws and regulations, HBW-3-20 will follow the fast track of orphan drug development and will be used in clinical practice more quickly.

Based on Haibowei's rich experience in developing BTK inhibitors and excellent preclinical data, a number of leading pharmaceutical companies have expressed a strong desire to jointly develop second-generation BTK inhibitors with Haibowei.

4 INDs will be declared this year and next two years, and the preclinical data of multiple projects under research will surpass similar clinical drugs of the world's leading pharmaceutical companies

At present, the second-generation anti-drug resistant BTK inhibitors that have entered the clinical stage are only Lilly’s LOXO-305 and Merck’s ARQ-531.
In the pre-clinical head-to-head comparison experiment, HBW-3-10 significantly surpassed the ARQ-531, which Merck bought for more than US$2 billion in terms of in vivo and in vitro activity, pharmacokinetics, and toxicology, and has just entered the second phase of clinical trials.
There is a great opportunity.
Become a Best-in-class second-generation anti-drug resistant BTK inhibitor.
In addition, Haibowei also expects to complete 4 IND declarations before the end of next year.

In June of this year, Haibowei's two anti-tumor project-related articles will be presented at one of the most important clinical oncology annual conferences in the world-the American Society of Clinical Oncology (ASCO) annual conference.
This marks Haibo's steady progress towards the goal of internationalization.

In the future, Haibo will continue to learn from the world's first-class pharmaceutical companies, and gradually move towards internationalization, and will always adhere to the three-first principle of leading concept, leading strategy, and leading technology, and do more for mankind with better quality and price.
"Excellent" medicine has become an innovative medicine company recognized by international peers.

About Waige Capital

Waige Capital is a private equity investment fund based on the two-wheel drive of "VC investment" + "IPO investment bank", focusing on the health industry.
The management team has a wealth of medical and health industry background and equity investment experience.

Waige’s investment projects include Kangdelai Medical Devices (1501.
HK) [Interventional Medical Devices], Corfu Medical [Home Medical Devices], Beststar [Clinical CRO], Wei Li Zhibo [New Drug Research and Development], Zhidao Bio[ New drug research and development], Zhongyi Anke [vaccine research and development], rispril [inhalation preparations], Haibowei [new drug research and development], Shengsi Biology [new drug research and development], Kaifu Pharmaceutical [new drug research and development], Huajian Future[ New Drug Research and Development], Junyue Pharmaceutical [Apparatus CRO], Xinnuo Medical [Animal Experiment Center], Ruiyi Technology [Medicine CDMO], Better Micro Medical [Interventional Medical Devices] and many other high-quality enterprises.

About Sichuan Academician Fund

The fund was initiated and established by Sichuan Development.
The first phase of the fund is 1 billion yuan.
It is a theme fund that accurately serves high-level talents such as academicians of the two academies, and aims to better promote the transformation and landing of high-level scientific and technological innovation achievements in Sichuan.
As a rare trillion-level local state-owned enterprise in the western region and even the whole country, Sichuan Development has played an active role in the establishment of the fund.

Next, Sichuan Development will closely contact more academicians of the two academies, tailor-made implementation plans for the transformation of scientific and technological achievements for academicians, and make every effort to build the academician fund into a link and platform for the incubation and cultivation of academician scientific and technological achievements.

The Sichuan Provincial Party Committee and Government has always attached great importance to scientific and technological innovation and the introduction of talents, and regarded this as an important measure to accelerate the construction of a scientific and technological innovation center with national influence.
Last year, the province's high-tech industry operating income exceeded 2 trillion yuan.
In addition to the ten measures released last year to support the innovation and entrepreneurship of academicians of the two academies in Sichuan, a series of new measures are steadily advancing.